Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. PFE Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Pfizer (PFE)

Market Price (9/16/2025): $23.98 | Market Cap: $136.3 Bil
Sector: Health Care | Industry: Pharmaceuticals

Pfizer (PFE)

Market Price (9/16/2025): $23.98
Market Cap: $136.3 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 13%, Dividend Yield is 5.3%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 8.7%, FCF Yield is 9.1%		 Weak multi-year price returns
2Y Excs Rtn is -67%, 3Y Excs Rtn is -105%		 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -12%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19%, CFO LTM is 15 Bil, FCF LTM is 12 Bil		  
3 Low stock price volatility
Vol 12M is 25%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 13%, Dividend Yield is 5.3%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 8.7%, FCF Yield is 9.1%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19%, CFO LTM is 15 Bil, FCF LTM is 12 Bil
3 Low stock price volatility
Vol 12M is 25%
4 Weak multi-year price returns
2Y Excs Rtn is -67%, 3Y Excs Rtn is -105%
5 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -12%

Market Valuation

 9/16/252024202320222021
Share Price CYE$23.98$25.18$25.75$43.83$48.93
Market Cap CYE ($ Bil)136.3142.7145.4246.1274.6
Total Debt ($ Bil)60.963.670.834.937.0
Total Cash ($ Bil)13.220.512.722.731.1
Enterprise Value ($ Bil)184.0206.3216.2281.0311.6
Valuation Ratios     
P/S TTM2.12.42.72.84.1
P/EBIT TTM10.213.549.78.012.9
P/E TTM12.718.776.79.215.1
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.9-1.6-1.5-1.4-2.9
 9/16/2520242023
Share Price CYE$23.98$25.18$25.75
Market Cap CYE ($ Bil)136.3142.7145.4
Total Debt ($ Bil)60.963.670.8
Total Cash ($ Bil)13.220.512.7
Enterprise Value ($ Bil)184.0206.3216.2
Valuation Ratios   
P/S TTM2.12.42.7
P/EBIT TTM10.213.549.7
P/E TTM12.718.776.7
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.9-1.6-1.5

Market Cap Chart

Business Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
PFE Return-2%67%-10%-41%-2%-5%-20%
Peers Return7%30%20%-3%7%-3%67%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: LLY, JNJ, MRK, BMY, PFE. See PFE Returns vs. Peers.
[3] 2025 data is for the year up to 9/15/2025 (YTD)

Interactive Breakdown

Pfizer Interactive Breakdown Analysis

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Pfizer Earnings Notes  
2Ten-Year Tally: PFE Hands Back $50 Bil to Shareholders  
3Pfizer vs Verizon Communications: Which Is A Better Investment?Counter-Intuitive Comparisons 
4Pfizer vs Royalty Pharma: Which Is A Better Investment?Counter-Intuitive Comparisons 
5Pfizer vs Innoviva: Which Is A Better Investment?Counter-Intuitive Comparisons 
6With 47% Gains On The Table, LLY May Outshine PFEActionable 
7PFE's 5.2% One Day Pop Begs The Question: Is INVA Better Instead?Counter-Intuitive Comparisons 
8Pfizer vs. Comcast: Both Seem Similar BetsPeer Comparison 
9Pfizer vs. Honeywell International: Both Seem Similar BetsPeer Comparison 
10Pfizer vs. Stryker: With Return Forecast Of 25%, Stryker Is A Better BetPeer Comparison 
11ARTICLES  
12PFE Has Paid Out $50 Bil to Investors in the Past Decade September 6th, 2025
13Time To Buy Pfizer Stock? August 28th, 2025
14What’s Next For Pfizer Stock After A Solid Q2? August 5th, 2025
15How To Trade Pfizer Stock Ahead of Its Upcoming Earnings? August 1st, 2025
16Pfizer And Drug Pricing: Should You Invest Now? May 13th, 2025
Title
0DASHBOARDS
1PFE Has Paid Out $50 Bil to Investors in the Past Decade
2Time To Buy Pfizer Stock?
3What’s Next For Pfizer Stock After A Solid Q2?
4How To Trade Pfizer Stock Ahead of Its Upcoming Earnings?
5Pfizer And Drug Pricing: Should You Invest Now?
6ARTICLES
7Pfizer Earnings Notes
8Ten-Year Tally: PFE Hands Back $50 Bil to Shareholders
9Pfizer vs Verizon Communications: Which Is A Better Investment?
10Pfizer vs Royalty Pharma: Which Is A Better Investment?
11Pfizer vs Innoviva: Which Is A Better Investment?
12With 47% Gains On The Table, LLY May Outshine PFE
13PFE's 5.2% One Day Pop Begs The Question: Is INVA Better Instead?
14Pfizer vs. Comcast: Both Seem Similar Bets
15Pfizer vs. Honeywell International: Both Seem Similar Bets
16Pfizer vs. Stryker: With Return Forecast Of 25%, Stryker Is A Better Bet

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NXTTNext Technology18985.5%1080.3%
2BDSXBiodesix1658.4%-75.2%
3VCIGVCI Global1460.0%-66.8%
4CLSDClearside Biomedical1075.2%-72.3%
5SDOTSadot806.7%-78.2%
6WLDSWearable Devices539.8%-24.4%
7QMMMQMMM536.6%5505.5%
8ATCHAtlasClear382.9%-89.7%
9OPIOffice Properties Income Trust274.5%-8.3%
10CWDCaliberCos246.5%-46.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1DGNXDiginex-83.7% 
2ATYRaTyr Pharma-81.4%-72.0%
3LGCLLucas GC-73.2%-78.3%
4NAKAKindly MD-72.8% 
5OCTOEightco-67.8%562.1%
6YYGHYY-67.0%-78.2%
7SNTGSentage-58.1%57.5%
8REXREX American Resources-50.7%-26.7%
9BINIBollinger Innovations-49.2%-100.0%
10SLXNSilexion Therapeutics-49.2%-88.0%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO7309.3% 
3CHSNChanson International5551.3%-99.3%
4LNZALanzaTech Global5145.9%-85.7%
5QMMMQMMM2490.3%5505.5%
6NXTTNext Technology2167.7%1080.3%
7VTAKCatheter Precision1543.9%-70.5%
8CURXCuranex Pharmaceuticals1282.0%1282.0%
9VCIGVCI Global1278.3%-66.8%
10OCTOEightco800.6%562.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-93.3%-95.1%
2ELPWElong Power-92.4%-76.5%
3STFSStar Fashion Culture-92.1%-97.9%
4ETSElite Express-92.0%-92.0%
5NAKAKindly MD-91.7% 
6BINIBollinger Innovations-90.5%-100.0%
7FLYEFly-E-89.8%-81.2%
8JEM707 Cayman-89.8%-98.3%
9NUTRNusaTrip-86.7%-86.7%
10CUPRCuprina-84.9% 

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NXTTNext Technology18985.5%1080.3%
2BDSXBiodesix1658.4%-75.2%
3VCIGVCI Global1460.0%-66.8%
4CLSDClearside Biomedical1075.2%-72.3%
5SDOTSadot806.7%-78.2%
6WLDSWearable Devices539.8%-24.4%
7QMMMQMMM536.6%5505.5%
8ATCHAtlasClear382.9%-89.7%
9OPIOffice Properties Income Trust274.5%-8.3%
10CWDCaliberCos246.5%-46.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1DGNXDiginex-83.7% 
2ATYRaTyr Pharma-81.4%-72.0%
3LGCLLucas GC-73.2%-78.3%
4NAKAKindly MD-72.8% 
5OCTOEightco-67.8%562.1%
6YYGHYY-67.0%-78.2%
7SNTGSentage-58.1%57.5%
8REXREX American Resources-50.7%-26.7%
9BINIBollinger Innovations-49.2%-100.0%
10SLXNSilexion Therapeutics-49.2%-88.0%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Pfizer

Financials

PFELLYJNJMRKBMYMedian
NamePfizer Eli LillyJohnson .Merck Bristol-. 
Mkt Price23.97748.19177.4081.0246.3581.02
Mkt Cap136.3671.8426.9203.494.1203.4
Rev LTM63,83353,25890,62763,61647,63663,616
Op Inc LTM16,66322,88222,22819,8217,87019,821
FCF LTM12,438-5016,39714,72213,08613,086
FCF 3Y Avg9,304-15616,92612,89912,22512,225
CFO LTM15,18810,93823,02818,53414,31015,188
CFO 3Y Avg12,5847,23022,24816,76613,41913,419

Growth & Margins

PFELLYJNJMRKBMYMedian
NamePfizer Eli LillyJohnson .Merck Bristol-. 
Rev Chg LTM13.5%36.8%4.7%1.8%4.6%4.7%
Rev Chg 3Y Avg-12.4%23.4%4.0%3.7%0.5%3.7%
Rev Chg Q10.3%37.6%5.8%-1.9%-5.6%5.8%
QoQ Delta Rev Chg LTM2.2%8.7%1.5%-0.5%-1.4%1.5%
Op Mgn LTM26.1%43.0%24.5%31.2%16.5%26.1%
Op Mgn 3Y Avg20.2%35.6%26.3%22.6%17.3%22.6%
QoQ Delta Op Mgn LTM1.8%1.8%-0.2%-0.8%4.3%1.8%
CFO/Rev LTM23.8%20.5%25.4%29.1%30.0%25.4%
CFO/Rev 3Y Avg18.8%17.8%25.7%27.2%28.9%25.7%
FCF/Rev LTM19.5%-0.1%18.1%23.1%27.5%19.5%
FCF/Rev 3Y Avg13.8%0.5%19.6%20.9%26.4%19.6%

Valuation

PFELLYJNJMRKBMYMedian
NamePfizer Eli LillyJohnson .Merck Bristol-. 
Mkt Cap136.3671.8426.9203.494.1203.4
P/S2.112.64.73.22.03.2
P/EBIT10.237.815.110.011.611.6
P/E12.748.718.812.417.417.4
P/CFO9.061.418.511.06.611.0
Total Yield13.2%2.8%8.1%12.0%11.0%11.0%
Dividend Yield5.3%0.7%2.8%3.9%5.2%3.9%
FCF Yield 3Y Avg5.7%0.1%4.5%5.1%12.4%5.1%
D/E0.40.10.10.20.50.2
Net D/E0.30.10.10.10.40.1

Returns

PFELLYJNJMRKBMYMedian
NamePfizer Eli LillyJohnson .Merck Bristol-. 
1M Rtn-4.7%6.7%1.2%-2.8%-4.3%-2.8%
3M Rtn-0.1%-7.2%15.1%1.1%-4.7%-0.1%
6M Rtn-4.6%-8.9%10.7%-12.8%-21.9%-8.9%
12M Rtn-12.4%-18.4%10.6%-27.0%-2.5%-12.4%
3Y Rtn-38.6%148.4%16.0%1.0%-27.4%1.0%
1M Excs Rtn-6.8%7.3%0.0%-3.4%-5.3%-3.4%
3M Excs Rtn-11.3%-19.2%3.1%-9.5%-17.5%-11.3%
6M Excs Rtn-20.7%-24.9%-6.6%-29.2%-37.9%-24.9%
12M Excs Rtn-32.6%-37.2%-8.0%-45.4%-20.5%-32.6%
3Y Excs Rtn-105.1%78.0%-47.6%-63.0%-90.3%-63.0%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/29/20253/30/202512/31/20249/29/20246/30/20243/31/202412/31/202310/1/20237/2/20234/2/202312/31/202210/2/2022
Filing Date8/5/20255/5/20252/27/202511/4/20248/5/20245/8/20242/22/202411/8/20238/9/20235/10/20232/23/202311/9/2022
Key Financials Quarterly            
Total Revenue14,65313,71517,76417,70113,28314,87814,56913,49213,00618,48525,13522,638
Ebitda5,3235,0572,5207,2532,4065,947-1,771-1,0974,3508,0757,06310,495
Operating Income3,7674,4253,1875,2842,2634,203-1,651-2,9482,4406,5736,0969,666
Net Income2,9102,9674104,465413,115-3,369-2,3822,3275,5434,9948,608
EPS0.510.520.070.790.010.55-0.60-0.420.410.980.891.54
Key Financials TTM            
Total Revenue TTM63,83362,46363,62660,43156,22255,94559,55270,11879,26494,000101,17699,879
Ebitda TTM20,15317,23618,12613,8355,4857,4299,55718,39129,98338,54841,03239,447
Operating Income TTM16,66315,15914,93710,0991,8672,0444,41412,16124,77534,74438,11937,618
Net Income TTM10,7527,8838,0314,252-2,595-3092,11910,48221,47229,05131,37229,771
Growth Rates Quarterly            
Total Revenue Growth10.3%-7.8%21.9%31.2%2.1%-19.5%-42.0%-40.4%-53.1%-28.0%5.4%-5.8%
EBITDA Growth121.2%-15.0%242.3%761.2%-44.7%-26.4%-125.1%-110.5%-66.3%-23.5%28.9%10.4%
Operating Income Growth66.5%5.3%293.0%279.2%-7.3%-36.1%-127.1%-130.5%-80.3%-33.9%9.0%27.9%
Net Income Growth6997.6%-4.8%112.2%287.4%-98.2%-43.8%-167.5%-127.7%-76.5%-29.5%47.2%5.7%
Margins Quarterly            
EBITDA Margin36.3%36.9%14.2%41.0%18.1%40.0%-12.2%-8.1%33.4%43.7%28.1%46.4%
Operating Income Margin25.7%32.3%17.9%29.9%17.0%28.2%-11.3%-21.8%18.8%35.6%24.3%42.7%
Net Income Margin19.9%21.6%2.3%25.2%0.3%20.9%-23.1%-17.7%17.9%30.0%19.9%38.0%
Cash & Debt            
Total Cash13,24917,31620,4779,9527,10111,92912,69044,18144,78519,97222,73236,123
Total Debt60,92661,29163,64966,61768,67768,70870,84563,59665,34134,92734,85935,677
Net Debt / (Cash)47,67743,97543,17256,66561,57656,77958,15519,41520,55614,95512,127-446
Cash Flows Quarterly            
FCF from Operations-5822,3356,7216,714-1,7811,0905,2403,456-1,2081,2128,5825,974
Cash Flows TTM            
FCF from Operations TTM15,18813,98912,74411,2638,0058,5788,70012,04214,56023,93829,26726,599
Returns to Shareholders Quarterly            
Dividends2,4452,4372,3802,3802,3802,3722,3152,3142,3152,3032,2452,245
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC30.1%40.3%29.5%35.4%14.7%27.1%-9.2%-43.3%47.5%155.8%192.2%-
Return on Invested Capital (ROIC) TTM            
ROIC TTM34.9%34.5%34.6%17.8%1.9%0.5%7.6%62.6%114.0%211.4%284.2%-

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Biopharma58,23799,82679,55740,72438,013
Other business activities1,3161,3491,7319262,892
Total59,553101,17581,28841,65040,905


Price Behavior

PFE Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-0.47-0.180.120.480.430.44
Up Beta0.24-0.07-0.110.350.350.38
Down Beta-0.56-0.770.290.680.630.61
Up Capture-17%-1%31%36%19%7%
Bmk +ve Days10223571142415
Stock +ve Days14213264123351
Down Capture-159%-7%-5%62%55%79%
Bmk -ve Days11192754106334
Stock -ve Days6192959123392

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity103,465,144
Short Interest: % Change Since 8152025-9.1%
Average Daily Volume36,433,348
Days-to-Cover Short Interest2.84
Basic Shares Quantity5,685,000,000
Short % of Basic Shares1.8%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/5/20255.2%4.5%5.4%
4/29/20253.2%3.6%2.5%
2/4/2025-1.3%-1.3%-1.0%
10/29/2024-1.4%-3.8%-9.3%
7/30/20242.2%-3.2%-6.2%
5/1/20246.1%8.4%11.7%
1/30/2024-1.7%-3.3%-1.6%
10/13/20233.6%-4.5%-8.5%
...
SUMMARY STATS   
# Positive131110
# Negative111314
Median Positive3.2%3.2%7.0%
Median Negative-1.4%-3.3%-5.1%
Max Positive6.1%11.7%26.4%
Max Negative-5.0%-6.4%-12.7%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025805202510-Q 6/29/2025
3312025505202510-Q 3/30/2025
12312024227202510-K 12/31/2024
93020241104202410-Q 9/29/2024
6302024805202410-Q 6/30/2024
3312024508202410-Q 3/31/2024
12312023222202410-K 12/31/2023
93020231108202310-Q 10/1/2023
6302023809202310-Q 7/2/2023
3312023510202310-Q 4/2/2023
12312022223202310-K 12/31/2022
93020221109202210-Q 10/2/2022
6302022810202210-Q 7/3/2022
3312022511202210-Q 4/3/2022
12312021224202210-K 12/31/2021
93020211112202110-Q 10/3/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0BLAYLOCK RONALD E 2142025Buy25.6519,457499,072710,685Form
1Gottlieb Scott 10312024Buy28.241,00028,240282,400Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.